1. Home
  2. SWTX vs BHF Comparison

SWTX vs BHF Comparison

Compare SWTX & BHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWTX
  • BHF
  • Stock Information
  • Founded
  • SWTX 2017
  • BHF 2016
  • Country
  • SWTX United States
  • BHF United States
  • Employees
  • SWTX N/A
  • BHF N/A
  • Industry
  • SWTX Biotechnology: Pharmaceutical Preparations
  • BHF Life Insurance
  • Sector
  • SWTX Health Care
  • BHF Finance
  • Exchange
  • SWTX Nasdaq
  • BHF Nasdaq
  • Market Cap
  • SWTX 3.5B
  • BHF 3.4B
  • IPO Year
  • SWTX 2019
  • BHF N/A
  • Fundamental
  • Price
  • SWTX $47.00
  • BHF $53.77
  • Analyst Decision
  • SWTX Buy
  • BHF Hold
  • Analyst Count
  • SWTX 7
  • BHF 10
  • Target Price
  • SWTX $56.86
  • BHF $57.90
  • AVG Volume (30 Days)
  • SWTX 4.5M
  • BHF 748.6K
  • Earning Date
  • SWTX 08-06-2025
  • BHF 08-06-2025
  • Dividend Yield
  • SWTX N/A
  • BHF N/A
  • EPS Growth
  • SWTX N/A
  • BHF N/A
  • EPS
  • SWTX N/A
  • BHF 8.45
  • Revenue
  • SWTX $219,670,000.00
  • BHF $8,610,000,000.00
  • Revenue This Year
  • SWTX $74.36
  • BHF $41.29
  • Revenue Next Year
  • SWTX $75.63
  • BHF $2.39
  • P/E Ratio
  • SWTX N/A
  • BHF $6.35
  • Revenue Growth
  • SWTX 730.42
  • BHF 165.09
  • 52 Week Low
  • SWTX $28.21
  • BHF $40.00
  • 52 Week High
  • SWTX $62.00
  • BHF $64.12
  • Technical
  • Relative Strength Index (RSI)
  • SWTX 63.86
  • BHF 38.22
  • Support Level
  • SWTX $46.93
  • BHF $51.35
  • Resistance Level
  • SWTX $47.02
  • BHF $62.73
  • Average True Range (ATR)
  • SWTX 0.08
  • BHF 2.12
  • MACD
  • SWTX -0.06
  • BHF -0.57
  • Stochastic Oscillator
  • SWTX 90.32
  • BHF 21.27

About SWTX SpringWorks Therapeutics Inc.

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.

About BHF Brighthouse Financial Inc.

Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.

Share on Social Networks: